Tagworks Pharmaceuticals BV, a precision oncology company, has appointed Ken Mills as Chief Executive Officer and member of the Board of Directors.
 
As part of this planned CEO leadership transition, Marc Robillard, Ph.D., the founding CEO of Tagworks, will continue in the role of Chief Scientific Officer and as a board member.
 
“Ken brings a wealth of valuable experience and understanding in bringing novel treatments to patients, combined with a strong track record in company building, and we are delighted to add his leadership to the team,” said Robillard.

About Ken Mills

Mills is a more than 25-year veteran of the biotechnology and pharmaceutical industries. Prior to joining Tagworks, he was the founding CEO, President, and Director of REGENXBIO, a clinical-stage and publicly traded biopharmaceutical company focused on the development and commercialization of adeno-associated virus (AAV) gene therapy. He oversaw several financing rounds, multiple phases of clinical trials, and led the company through an IPO.
 
During his tenure at REGENXBIO, Mills was also involved in the licensing and advising of a number of biotechnology companies, such as AveXis (Novartis) and Audentes (Astellas), as well as the launch of companies such as Dimension Therapeutics (Ultragenyx), Prevail Therapeutics (Eli Lilly), and Corlieve Therapeutics (UniQure). He is Chairman of the Board at REGENXBIO.
 
In addition, he was a Partner at FOXKISER, working to advise and launch companies in the biopharma space. Mills received his S.B. in Chemistry from Massachusetts Institute of Technology.
 
“Tagworks has differentiated science and is uniquely positioned to expand the potential of ADCs to safely and potently treat a wide spectrum of cancers by targeting biology that has remained beyond the reach of current therapies,” said Mills. “The milestones Marc and the team have accomplished in building the company, its novel treatment platform, and advancing the first clinical candidates sets a strong foundation for us as a company. I am thrilled to join this committed and talented team to help drive the development of the Company’s lead clinical ADC candidate, TGW101, and partner with Marc on the expansion of the Click-to-Release treatment platform and therapeutic pipeline to create precision medicines across multiple cancer types.”